Lucy Bailey1, Laura Moreno1, Tobias Manigold2, Sebastian Krasniqi2, Harald Kropshofer2, Heather Hinton2, Thomas Singer2, Laura Suter2, Trevor T Hansel3, Jane A Mitchell4. 1. Cardiothoracic Pharmacology, National Heart and Lung Institute (NHLI), Imperial College, London, UK. 2. Non-Clinical Safety, Hoffmann-La Roche Ltd., Basel, Switzerland. 3. Imperial Clinical Respiratory Research Unit (ICRRU), NHLI, Imperial College, London, UK. 4. Cardiothoracic Pharmacology, National Heart and Lung Institute (NHLI), Imperial College, London, UK. Electronic address: j.a.mitchell@ic.ac.uk.
Abstract
INTRODUCTION: In 2006 the anti-CD28 superagonistic IgG4 TGN1412, having passed pre-clinical safety screens, caused a severe 'cytokine storm' in 6 healthy volunteers. Others have shown that for TGN1412 to induce an inflammatory signal in human peripheral blood mononuclear cells (PBMCs) or in human diluted blood, endothelial cells or bound monoclonal antibody (mAb) is required as part of a bioassay complex. These types of protocols rely on different donor cells and therefore have limitations as bioassays for pre-clinical testing. METHODS: We performed studies using human PBMC/endothelial cell co-cultures, whole blood/endothelial cell co-cultures and human whole blood alone. We bracketed responses of a CD28 superagonist antibody with mAbs against CD52 (alemtuzumab, MabCampath-1H) or epidermal growth factor receptor (cetuximab, Erbitux) and with the immunostimulant lipopolysaccharide. We detected cytokine responses at the level of protein release (using ELISAs and Luminex assays) and gene induction (using real-time PCR arrays). RESULTS: Here we confirm that IL-8 release was induced in a mixed endothelial cell-PBMC system by the anti-CD28 mAb. We go on to show that an alemtuzumab and an anti-CD28 mAb, but not cetuximab induced the release of a range of cytokines including IL-8, IL-6, IFNγ, IL-2 and IL10 after 24h and induced cytokine gene induction after 1h. Co-cultures of whole blood and HUVECS showed larger variability but no superiority over whole blood alone at a range of time points (0.5-48h). DISCUSSION: We suggest that, whilst limitations exist, human blood-based in vitro assays may prove useful in assessing the potential of mAbs and other biotherapeutics to cause release of cytokines in humans.
INTRODUCTION: In 2006 the anti-CD28 superagonistic IgG4 TGN1412, having passed pre-clinical safety screens, caused a severe 'cytokine storm' in 6 healthy volunteers. Others have shown that for TGN1412 to induce an inflammatory signal in human peripheral blood mononuclear cells (PBMCs) or in human diluted blood, endothelial cells or bound monoclonal antibody (mAb) is required as part of a bioassay complex. These types of protocols rely on different donor cells and therefore have limitations as bioassays for pre-clinical testing. METHODS: We performed studies using human PBMC/endothelial cell co-cultures, whole blood/endothelial cell co-cultures and human whole blood alone. We bracketed responses of a CD28 superagonist antibody with mAbs against CD52 (alemtuzumab, MabCampath-1H) or epidermal growth factor receptor (cetuximab, Erbitux) and with the immunostimulant lipopolysaccharide. We detected cytokine responses at the level of protein release (using ELISAs and Luminex assays) and gene induction (using real-time PCR arrays). RESULTS: Here we confirm that IL-8 release was induced in a mixed endothelial cell-PBMC system by the anti-CD28 mAb. We go on to show that an alemtuzumab and an anti-CD28 mAb, but not cetuximab induced the release of a range of cytokines including IL-8, IL-6, IFNγ, IL-2 and IL10 after 24h and induced cytokine gene induction after 1h. Co-cultures of whole blood and HUVECS showed larger variability but no superiority over whole blood alone at a range of time points (0.5-48h). DISCUSSION: We suggest that, whilst limitations exist, human blood-based in vitro assays may prove useful in assessing the potential of mAbs and other biotherapeutics to cause release of cytokines in humans.
Authors: Sandrine Vessillier; Madeline Fort; Lynn O'Donnell; Heather Hinton; Kimberly Nadwodny; Joseph Piccotti; Peter Rigsby; Karin Staflin; Richard Stebbings; Divya Mekala; Aarron Willingham; Babette Wolf Journal: Cytokine X Date: 2020-12
Authors: Nada S Alakhras; Jiabin Qiu; Guilherme V Rocha; Derrick R Witcher; Anja Koester; Jinsam You; David A Schaer; Rikke B Holmgaard; Kyla Driscoll; Jeffrey A Willy; Laurent P Malherbe Journal: MAbs Date: 2018-07-26 Impact factor: 5.857
Authors: Jesús Zurdo; Andreas Arnell; Olga Obrezanova; Noel Smith; Ramón Gómez de la Cuesta; Thomas R A Gallagher; Rebecca Michael; Yvette Stallwood; Caroline Ekblad; Lars Abrahmsén; Ingmarie Höidén-Guthenberg Journal: Biomed Res Int Date: 2015-05-17 Impact factor: 3.411
Authors: S Vessillier; D Eastwood; B Fox; J Sathish; S Sethu; T Dougall; S J Thorpe; R Thorpe; R Stebbings Journal: J Immunol Methods Date: 2015-05-07 Impact factor: 2.303